Product Monograph - Cerezyme (Sanofi-Aventis Canada)
RECENT MAJOR LABEL CHANGES
| 3 SERIOUS WARNINGS AND PRECAUTIONS BOX | 10/2024 |
|---|---|
| 7 WARNINGS AND PRECAUTIONS | 03/2025 |
Sections or subsections that are not applicable at the time of authorization are not listed.
TABLE OF CONTENTS .............................................................................................................. 2
RECENT MAJOR LABEL CHANGES............................................................................................ 2
PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4
1 INDICATIONS .............................................................................................................. 4
1.1 Pediatrics .......................................................................................................... 4
1.2 Geriatrics........................................................................................................... 4
2 CONTRAINDICATIONS ................................................................................................. 4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5
4 DOSAGE AND ADMINISTRATION................................................................................. 5
4.1 Dosing Considerations ....................................................................................... 5
4.2 Recommended Dose and Dosage Adjustment..................................................... 5
4.3 Reconstitution ................................................................................................... 5
4.4 Administration................................................................................................... 6
4.5 Missed Dose ...................................................................................................... 6
5 OVERDOSAGE ............................................................................................................. 7
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................................. 7
7 WARNINGS AND PRECAUTIONS .................................................................................. 7
7.1 Special Populations .......................................................................................... 13
7.1.1 Pregnant Women ....................................................................................... 13
7.1.2 Breast-feeding............................................................................................ 13
7.1.3 Pediatrics ................................................................................................... 13
7.1.4 Geriatrics ................................................................................................... 13
8 ADVERSE REACTIONS ................................................................................................ 14
8.2 Clinical Trial Adverse Reactions ........................................................................ 14
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other
Quantitative Data ...................................................................................................... 15
8.5 Post-Market Adverse Reactions........................................................................ 15
9 DRUG INTERACTIONS................................................................................................ 18
9.4 Drug-Drug Interactions .................................................................................... 18
9.5 Drug-Food Interactions .................................................................................... 18
9.6 Drug-Herb Interactions .................................................................................... 18
9.7 Drug-Laboratory Test Interactions .................................................................... 18
10 CLINICAL PHARMACOLOGY ....................................................................................... 18
10.1 Mechanism of Action.................................................................................. 18
10.2 Pharmacodynamics .................................................................................... 19
10.3 Pharmacokinetics ....................................................................................... 19
11 STORAGE, STABILITY AND DISPOSAL ......................................................................... 20
PART II: SCIENTIFIC INFORMATION ...................................................................................... 20
13 PHARMACEUTICAL INFORMATION............................................................................ 20
14 CLINICAL TRIALS........................................................................................................ 23
14.1 Clinical Trials by Indication.......................................................................... 23
15 MICROBIOLOGY ........................................................................................................ 27
16 NON-CLINICAL TOXICOLOGY ..................................................................................... 27
PATIENT MEDICATION INFORMATION ................................................................................. 29
PART I: HEALTH PROFESSIONAL INFORMATION
1 INDICATIONS
CEREZYME® (imiglucerase for injection) is indicated for:
- long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit non-neurological manifestations of the disease.
The non-neurological manifestations of Gaucher disease include one or more of the following conditions:
- anemia after exclusion of other causes, such as iron deficiency
- thrombocytopenia
- bone disease after exclusion of other causes such as Vitamin D deficiency
- hepatomegaly or splenomegaly
1.1 Pediatrics
Pediatrics (2 - 16 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of Cerezyme in pediatric patients aged 2 to 16 years have been established. Therefore, Health Canda has authorized an indication for pediatric use in patients aged 2 to 16 years. Use of Cerezyme in these age groups is supported by evidence from well-controlled studies of Cerezyme in adult and pediatric patients, with additional data obtained from the literature and from long term follow-up information.
Pediatrics (<2 years of age): No data are available to Health Canada for pediatric patients less than 2 years of age; therefore, Health Canada has not authorized an indication for pediatric use in patients less than 2 years of age.
1.2 Geriatrics
Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use.
2 CONTRAINDICATIONS
Imiglucerase is contraindicated in patients who are severely hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container (see 7 WARNINGS AND PRECAUTIONS). For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
Serious Warnings and Precautions
|
|---|
4 DOSAGE AND ADMINISTRATION
4.1 Dosing Considerations
- Disease severity may dictate that treatment be initiated at a relatively high dose or relatively frequent administration. Dosage adjustments should be made on an individual basis, and may increase or decrease, based on achievement of therapeutic goals as assessed by routine comprehensive evaluations of the patient’s clinical non-neurological manifestations.
- The efficacy of Cerezyme on neurological symptoms of chronic neuronopathic Gaucher patients has not been established.
- In situations where Cerezyme will be administered in a home care environment, it is suggested that the health care professional be trained and prepared for the possibility of an allergic-type reaction.
4.2 Recommended Dose and Dosage Adjustment
Dosage should be individualized to each patient. Treatment in pediatric and adult patients may be initiated from 2.5 units/kg of body weight 3 times a week up to 60 U/kg administered as frequently as once every two weeks. Titrate the dosage based on clinical manifestations of disease and therapeutic goals for the patient.
Higher doses (up to 120 U/kg every 2 weeks) have been given safely to Type 3 patients.
4.3 Reconstitution
Parenteral Products:
Preparation of Solution for Intravenous Infusion:
- 1. Using aseptic technique, reconstitute 400 U vial of Cerezyme with 10.2 mL of Sterile Water for Injection, USP, without preservatives. (Reconstitution yields a total volume 10.6 mL for the 400U vial). This results in a final concentration of 40 U/mL for each 400 U vial.
Table 1: Reconstitution
| Vial Size | Volume of Diluent to be Added to Vial | Approximate Available Volume | Nominal concentration per mL |
| 400 units | 10.2 mL Sterile Water for Injection, USP | 10.0 mL | 40 U/mL |
- 2. Gently swirl each vial to mix the solution. Important: Avoid excessive agitation during the reconstitution.
- 3. Bubbles may be present in the solution following reconstitution. Let the solution sit for several minutes to allow any bubbles to dissipate and the lyophilized product to be thoroughly dissolved.
- 4. The reconstituted preparation results in a clear solution. Inspect vials visually for particulate matter or discolouration before further dilution. Vials exhibiting opaque particles or discolouration should not be used. Because this is a protein solution, slight flocculation (described as thin translucent fibers) occurs occasionally after dilution.
Dilution
- 1. The total volume following dilution may vary from 100-200mL. The amount of Normal Saline within the range used for dilution does not affect the amount of Cerezyme administered to the patient.
- 2. Using aseptic technique, withdraw the contents of each vial and dilute it with 0.9% Sodium Chloride Injection, USP (Normal Saline) to a total volume of 100-200mL.
- 3. When more than 10 vials of Cerezyme are required, the drug itself prior to dilution yields a volume of 100 mL. The upper range (200mL) for total volume offers the flexibility for ensuring dilution of the drug in these instances.
- 4. Discard any unused portion remaining in the vials.
Since Cerezyme does not contain any antibacterial preservatives, it must be reconstituted and diluted immediately prior to administration (see 11 STORAGE, STABILITY AND DISPOSAL).
4.4 Administration
Cerezyme is administered by intravenous infusion over 1-2 hours. The maximum recommended infusion rate is 1 unit/kg/minute. The diluted solution may be filtered through an in-line low protein binding 0.2 µm filter during administration.
The vials are single use only. All unused portions must be discarded.
4.5 Missed Dose
It is important to have the infusion on a regular basis to avoid the accumulation of glucocerebroside. The total dose administered each month should remain substantially unchanged. If you have missed a dose, please contact your doctor.
5 OVERDOSAGE
Experience with doses up to 240 U/kg body weight every two weeks has been reported. At that dose, there have been no reports of obvious toxicity.
In the event of an overdose, stop the infusion immediately and monitor the patient closely in a hospital setting for the development of infusion-related reactions. For the management of adverse reactions, see 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS.
| For management of a suspected drug overdose, contact your regional poison control centre. |
|---|
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
To help ensure the traceability of biologic products, including biosimilars, health professionals should recognize the importance of recording both the brand name and the non-proprietary (active ingredient) name as well as other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.
Table 2: Dosage Forms, Strengths, Composition and Packaging
Cerezyme is intended for intravenous infusion. It is supplied as a sterile, non-pyrogenic, white to off-white lyophilized powder.
The total sodium citrate composition is made up of trisodium citrate and disodium hydrogen citrate in a ratio of 26:9.
Citric acid and/or sodium hydroxide may be present to adjust the pH to approximately 6.3.
Cerezyme is preservative-free.
Cerezyme is supplied in Type I glass vials capped with a 20 mm plastic cap and a flip-off aluminum crimp seal. Cerezyme is supplied in a 20 mL vial containing 400U (red label) of imiglucerase.
Individual cartons are available in shrink-wrapped bundles of 100, 108 and 120 vials.
7 WARNINGS AND PRECAUTIONS
General
Hypersensitivity reactions, including anaphylaxis and anaphylactic shock have been reported. Onset of such symptoms has occurred during or shortly after infusions; these symptoms include pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis, transient hypertension and hypotension. Treatment with Cerezyme should be approached with caution in patients who have exhibited symptoms of hypersensitivity to the product. Consider using pre-medication in patients with
| Route of Administration | Dosage Form / Strength/Composition | Non-medicinal Ingredients |
| Intravenous infusion | Lyophilized powder for reconstitution 400 Units | mannitol, nitrogen, polysorbate 80, sodium citrates (disodium hydrogen citrate and trisodium citrate) |
prior history of hypersensitivity with CEREZYME®. If hypersensitivity occurs, consider temporarily stopping or slowing the infusion and/or administering appropriate medication (see 4.1 Dosing Considerations;7 WARNINGS AND PRECAUTIONS ; and 8 ADVERSE REACTIONS).
If a severe hypersensitivity reaction occurs, stop administration of CEREZYME® and initiate appropriate medical treatment. The risks and benefits of re-administering CEREZYME® following a severe hypersensitivity or anaphylactic reaction should be considered.
Caution is advisable in administration of CEREZYME® to patients previously treated with placental-derived ß-glucocerebrosidase (alglucerase injection) and who have developed antibody or who have exhibited symptoms of hypersensitivity to placental-derived ß-glucocerebrosidase (alglucerase injection).
Immune
Cerezyme is contraindicated for patients who are severely hypersensitive (e.g., anaphylactic reactions) to this drug or to any ingredient in the formulation or component of the container (see 2 CONTRAINDICATIONS).
Patients should be closely monitored during the Cerezyme infusion. If significant/severe/life-threatening hypersensitivity reaction (e.g., anaphylactic reactions) occurs during or after infusions, Cerezyme infusion should be discontinued immediately and appropriate medical treatment should be initiated.
Treatment with Cerezyme should be approached with caution and be closely monitored during the infusion in patients who have the history of mild or moderate hypersensitivity reaction (e.g., eczema, pruritis, flushing, rash, etc) to the active ingredient or excipients in the drug product. Pre-treatment with antihistamines and/or corticosteroids and reduction in the rate of infusion has allowed continued use of Cerezyme in most patients.
Anaphylactoid reaction has been reported in less than 1% of the patient population. Further treatment with Cerezyme should be conducted with caution. Most patients have successfully continued therapy after a reduction in rate of infusion and pretreatment with antihistamines and/or corticosteroids. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue Cerezyme and immediately initiate appropriate medical treatment, including use of epinephrine. Consider the risks and benefits of readministering Cerezyme to individual patients following a severe reaction. If the decision is made to readminister the product, consider reducing the rate of infusion and pretreat with antihistamines and/or corticosteroids and monitor patients for the occurrence of new signs and symptoms of a severe hypersensitivity reaction. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur.
Data from clinical trials, using a screening enzyme-linked immunosorbent assay (ELISA) followed by a confirmatory radioimmunoprecipitation assay, suggest that approximately 15% of patients treated and tested to date have developed IgG antibody to Cerezyme during the first year of therapy. Patients who developed IgG antibody largely did so within 6 months of treatment and rarely developed antibodies to Cerezyme after 12 months of therapy. Approximately 46% of patients with detectable IgG antibodies experienced symptoms of hypersensitivity. It is recommended that patients suspected of a decreased response to treatment be monitored periodically for the formation of IgG antibody to imiglucerase. Patients with antibody to imiglucerase have a higher risk of hypersensitivity reactions. Patients who have developed antibodies or symptoms of hypersensitivity to placental-derived ß-glucocerebrosidase (alglucerase) should be treated with caution when Cerezyme (imiglucerase) is administered. However, not all patients with symptoms of hypersensitivity have detectable IgG antibodies.
Infusion-Related Reactions
Infusion-related reactions such as flushing, angioedema, pruritus, rash, urticaria, chest discomfort, dyspnea, bronchospasm, chills, fatigue, infusion-site burning, infusion-site discomfort, infusion-site swelling, pyrexia, transient hypertension, and hypotension have been observed in patients treated with Cerezyme.
The management of infusion-related reactions should be based on the severity of the reaction, e.g. slowing the infusion rate, treatment with medications such as antihistamines, antipyretics and/or corticosteroids, and/or stopping and resuming treatment with increased infusion time.
Pre-treatment with antihistamines and/or corticosteroids may prevent subsequent reactions in those cases where symptomatic treatment was required. Closely monitor patients who have experienced infusion-related reactions when re-administering Cerezyme.
Monitoring and Laboratory Tests
Patients with antibodies to Cerezyme have a higher risk of hypersensitivity reactions, although not all patients with symptoms of hypersensitivity have detectable IgG antibodies. It is suggested that patients be monitored periodically during the first year of therapy (approximately every 3 months) and at approximately 18 months for IgG antibody formation.
A comprehensive set of response parameters and treatment guidelines have been established and should be followed for the evaluation of Gaucher patients’ response to therapy. An ongoing database, known as the International Collaborative Gaucher Group (ICGG) Registry, has been established for the world-wide collection of uniform data to improve the understanding of the disease and the clinical response to enzyme replacement therapy (ERT). The Registry may be contacted at 1-800-745-4447 or information can be found at www.gaucherregistry.com. The Gaucher Registry should be used by Canadian physicians as a monitoring vehicle for all Gaucher patients in Canada. Enrollment of patients is the responsibility of the treating physician. The Registry will be used to monitor the long term effectiveness of ERT when used in the community. All references to specific patients should be made by initials or Registry identification (ID) number, not by name.
The parameters monitored by the Registry include hemoglobin, platelet count, spleen and liver volume, and location and degree of skeletal involvement. Recommended primary assessments and assessment schedules for various evaluations for untreated patients and those on ERT are presented in the tables below.
Table 3: Initial Assessment
| A complete history of patient and family, preferably including a pedigree |
|---|
| A comprehensive physical examination (annual) |
| Quality of life (annual): Patient-reported functional health and well-being (SF-36 Health Survey) |
|---|
Blood tests Primary tests
Biochemical markers (one or more of these biochemical markers should be consistently monitored in conjunction with other clinical assessments of disease activity; chitotriosidase, when available as a validated procedure, may be the most sensitive indicator of changing disease activity, and is therefore preferred, although approximately 5% of the general population do not express any chitotriosidase activity due to genetic variability in enzyme expression)
Additional blood tests (to be evaluated selectively based on each patient’s age and clinical status)
|
| β-glucosidase and mutation analysis |
| Antibody sample* |
Visceral (contiguous transaxial 10-mm thick sections for sum of region of interest) Spleen volume (volumetric MRI or CT) Liver volume (volumetric MRI or CT) |
Skeletal MRI (coronal; T1- and T2-weighted) of the entire femora X-ray (AP view of the entire femora)** and lateral view of the spine DXA lumbar spine and femoral neck |
Pulmonary (recommended every 12-24 months for patients with borderline or above normal pulmonary pressures at baseline) ECG, chest x-ray, and Doppler echocardiogram (right ventricular systolic pressure) for patients > 18 years old |
* A baseline sample to be stored at Genzyme Corporation; an optional subsequent sample at 6 months after starting enzyme replacement therapy (ERT). The samples will be tested only if clinically indicated such as for a suspected immune-mediated adverse event, or for suspected loss of ERT effectiveness.
** Optimally from hips to below knees
| Abbreviations: | |
|---|---|
|
|
Table 4: Ongoing Monitoring 1
| Parameters | Patients on Enzyme Therapy | |||||
|---|---|---|---|---|---|---|
| Patients Not on Enzyme Therapy | Not Achieved Therapeutic Goals | Achieved Therapeutic Goals | At Time of Dose Change or Significant Clinical Complication | |||
| Every 12 months | Every 12-24 months | Every 3 months | Every 12 months | Every 12-24 months | ||
| A comprehensive physical examination | X | X | X (annual) | |||
| SF-36 (QOL) survey | X | X | X (annual) | X | ||
Blood tests Hemoglobin Platelet Count | X X | X X | X X | X X | ||
Biochemical markers 2 Chitotriosidase ACE TRAP | X | X | X | X | ||
| Additional blood tests | To be followed appropriately if abnormal based on each patient’s age and clinical status | |||||
| Visceral (contiguous transaxial 10mm thick sections for | ||||||
| Parameters | Patients on Enzyme Therapy | |||||
|---|---|---|---|---|---|---|
| Patients Not on Enzyme Therapy | Not Achieved Therapeutic Goals | Achieved Therapeutic Goals | At Time of Dose Change or Significant Clinical Complication | |||
| Every 12 months | Every 12-24 months | Every 3 months | Every 12 months | Every 12-24 months | ||
sum of region of interest) Spleen volume (volumetric MRI or CT) Liver volume (volumetric MRI or CT) | X X | X X | X X | X X | ||
Skeletal 3 MRI of entire femora (coronal; T1- & T2- weighted) 4 X-ray 4,5 DXA | X X X | X X X | X X X | X X X | ||
| Pulmonary | Recommended every 12-24 months for patients with borderline or above normal pulmonary pressures at baseline | |||||
1 A comprehensive physical examination should be performed at least annually.
2 One or more of these biochemical markers should be consistently monitored every 12 months and in conjunction with other clinical assessments of disease activity and response to treatment; chitotriosidase, when available as a validated procedure, may be the most sensitive indicator of changing disease activity, and is therefore preferred.
3 Anatomical sites not included here should be evaluated if symptoms develop in such locations.
4 AP view of the entire femora (optimally from hips to below knees), and lateral view of the spine
5 Optional in absence of new symptoms or evidence of disease progression
Medical or health care professionals are encouraged to register Gaucher patients, including those with chronic neuronopathic manifestations of the disease, in the “ICGG Gaucher Registry”.
For more information please consult the Registry website: www.gaucherregistry.com.
Respiratory
In less than 1% of the patient population, pulmonary hypertension has also been observed during treatment with Cerezyme. Pulmonary hypertension is a known complication of Gaucher disease and has been observed both in patients receiving and not receiving Cerezyme. No causal relationship with Cerezyme has been established. Patients with respiratory symptoms should be evaluated for the presence of pulmonary hypertension.
7.1 Special Populations
7.1.1 Pregnant Women
There are no data from studies in pregnant women. It is unknown whether Cerezyme can cause fetal harm when administered to pregnant women or if it can affect reproductive capacity. It is unknown whether Cerezyme passes via the placenta to the developing fetus.
No animal studies have been carried out with respect to assessing the effects of Cerezyme on pregnancy, embryonal/fetal development, parturition and postnatal development.
The use of Cerezyme in pregnant women with Gaucher disease may be considered only after individual patient risk-benefit assessment has been made. In pregnant Gaucher patients and in those intending to become pregnant, a risk-benefit treatment assessment is required for each pregnancy. Irrespective of the decision about treatment, specific monitoring should be available throughout the pregnancy to ascertain or pre-empt complications related to the disease.
Limited experience on 158 pregnancy outcomes is available from the Sponsor pharmacovigilance database. Gaucher disease in pregnant women may be complicated by increase visceromegaly, worsening anemia, thrombocytopenia, bleeding, bone crises and osteonecrosis. Spontaneous abortions and fetal demises at any time in pregnant women receiving Cerezyme have been reported. The causal association with Cerezyme has not been established.
7.1.2 Breast-feeding
No well-controlled clinical trials were conducted in nursing women. It is unknown whether Cerezyme is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cerezyme is administered to nursing women.
7.1.3 Pediatrics
Pediatrics (< 2 years of age): No data are available to Health Canada for pediatric patients less than 2 years of age; therefore, Health Canada has not authorized an indication for pediatric use in patients less than 2 years of age.
Pediatrics (2 - 16 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of Cerezyme in pediatric patients aged 2 to 16 years have been established. Therefore, Health Canda has authorized an indication for pediatric use in patients aged 2 to 16 years.
7.1.4 Geriatrics
Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use.
8 ADVERSE REACTIONS
8.2 Clinical Trial Adverse Reactions
Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials therefore may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.
The following safety information is based on the 3 pre-marketing clinical studies completed prior to registration of Cerezyme: the Pivotal study (RC91-0110), the Extension study (RC92-0501) and the Israeli study (RC92-0301). All patients were Type 1 Gaucher patients. Cerezyme naïve patients refer to those patients who were randomized to receive Cerezyme for 6 months at a dose of 60 U/kg every 2 weeks during the Pivotal study and continued on Cerezyme during the Extension study. Cerezyme cross-over patients refer to those patients who were randomized to receive alglucerase injection during the Pivotal study then were switched to Cerezyme during the Extension study. Some dose reductions based on maintenance of efficacy occurred during the Extension study. The 10 patients in the Israeli study received Cerezyme for 18 to 24 months at doses of either 15 U/kg every other week or 2.5 U/kg three times weekly.
Table 5: All related adverse events (≥1%) in Cerezyme treated patients during the Pivotal, Extension and Israeli studies (by COSTART body system)
Cerezyme naïve (N=15) No. (%) | Cerezyme cross-over (N=15) No. (%) | Cerezyme Israeli Study (N=10) No. (%) | ||
|---|---|---|---|---|
| BODY AS A WHOLE | ||||
| Headache | 4 (27) | 0 (0) | 0 (0) | |
| Abdominal pain | 0 (0) | 0 (0) | 1 (10) | |
| Fever | 0 (0) | 1 (6.7) | 0 (0) | |
| Chest pain | 0 (0) | 1 (6.7) | 0 (0) | |
| CARDIOVASCULAR SYSTEM | ||||
| Hypotension | 1 (6.7) | 0 (0) | 0 (0) | |
| Vasodilation | 0 (0) | 1 (6.7) | 1 (10) | |
| DIGESTIVE SYSTEM | ||||
| Nausea | 1 (6.7) | 0 (0) | 1 (10) | |
| Diarrhea | 0 (0) | 1 (6.7) | 0 (0) | |
| NERVOUS SYSTEM | ||||
| Dizziness | 1 (6.7) | 0 (0) | 0 (0) | |
| Emotional lability | 0 (0) | 1 (6.7) | 0 (0) | |
Cerezyme naïve (N=15) No. (%) | Cerezyme cross-over (N=15) No. (%) | Cerezyme Israeli Study (N=10) No. (%) | ||
|---|---|---|---|---|
| Paresthesia | 0 (0) | 1 (6.7) | 0 (0) | |
| Hyperesthesia | 0 (0) | 0 (0) | 1 (10) | |
| Nervousness | 0 (0) | 0 (0) | 1 (10) | |
| SKIN AND APPENDAGES | ||||
| Pruritus | 1 (6.7) | 1 (6.7) | 0 (0) | |
| Rash | 1 (6.7) | 0 (0) | 0 (0) | |
| Rash macular-papular | 0 (0) | 1 (6.7) | 0 (0) | |
| UROGENITAL SYSTEM | ||||
| Oliguria | 1 (6.7) | 0 (0) | 0 (0) | |
During the 3 pre-marketing clinical studies, no additional adverse events were reported as potentially related to Cerezyme treatment. No serious adverse events were reported in any of the 3 studies.
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data
Clinical Trial Findings
In the Phase IV study (CZ-011-01), 5.6% (Q4 group) and 3.8% (Q2 group) of patients had shifts from normal at baseline to low hemoglobin levels at month 24. Patients who had shifts from normal at baseline to low platelet levels were 14.8% (Q4) and 3.8% (Q2) at month 3, 7.8% (Q4) and 0% (Q2) at month 12, and 16.7% (Q4) and 3.8% (Q2) at month 24.
In a Phase IV open-label study (RC96-1101, treated patients n = 33), 1 patient (3%) had an ALT value ≥ 5 x ULN and 5 (15%) others had an ALT value ≥ 1.5 x ULN; 2 patients (6%) had an AST value ≥ 3 x ULN and 2 (6%) others had an AST value ≥ 1.5 x ULN. Five patients (15%) had a bilirubin (total) value ≥ 1.5 x ULN.
8.5 Post-Market Adverse Reactions
Additional adverse events (AEs) have been identified during post-marketing use of Cerezyme. Due to the voluntary nature of post-marketing reporting and the continuous accrual and loss of patients over time, actual patient exposure and event frequencies are difficult to obtain and are therefore estimates. Post-marketing reports in patients treated with Cerezyme revealed that approximately 13.8% of patients experienced adverse drug reactions.
Hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported. Onset of such symptoms has occurred during or after infusions; these symptoms include pruritis, flushing, rash, urticaria/angioedema, chest discomfort, tachycardia, dyspnea, coughing, cyanosis, transient hypertension, paresthesia and backache. Hypotension associated with hypersensitivity has also been reported rarely (see 7 WARNINGS AND PRECAUTIONS, Immune).
Adverse drug reactions are listed by system organ class and frequency (common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100) and rare (≥1/10,000 to <1/1,000)) in the table below. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness.
Table 6: Adverse drug reactions are listed by system organ class and frequency
| Nervous system disorders | ||
| Uncommon: | Dizziness, headache | |
| Cardiac disorders | ||
| Uncommon: | Tachycardia, cyanosis | |
| Vascular disorders | ||
| Uncommon: | Flushing, hypotension | |
| Respiratory, thoracic and mediastinal disorders | ||
| Common: | Dyspnoea, coughing | |
| Gastrointestinal disorders | ||
| Uncommon: | Vomiting, nausea, abdominal cramping, diarrhea | |
| Immune system disorders | Common: Rare: | Hypersensitivity reactions Anaphylactoid reactions |
| Skin and subcutaneous tissue disorders | ||
| Common: | Urticaria/angioedema, pruritus, rash | |
Musculoskeletal and connective tissue disorders | ||
| Uncommon: | Backache | |
| General disorders and administration site conditions | ||
| Uncommon: | Infusion site discomfort, infusion site burning, infusion site swelling, injection site sterile abscess, chest discomfort, fever, rigors, fatigue | |
| Rare: | Transient peripheral edema | |
In addition to the adverse reactions that have been observed in patients treated with Cerezyme, transient peripheral edema has been reported for this therapeutic class of drug.
A completed post-marketing clinical study conducted in Japan (protocol 8-98) investigated the use of Cerezyme in patients with neuronopathic Gaucher disease. During this study, one Type 3 Gaucher patient experienced an AE of nail disorder which was considered potentially related to Cerezyme therapy. No additional adverse events were reported that were related to Cerezyme.
A Phase IV study (RC96-1101) was conducted to evaluate and quantify skeletal responses compared to baseline in patients receiving Cerezyme therapy over a period of 48 months. This was a multicenter, open-label, prospective study in treatment naïve patients (n = 33). The most common AEs were chills (7 events), flushing (6 events), and arthralgia (6 events), each reported in 4 patients (12%). The most common severe AEs were aseptic necrosis of bone and bone pain, both reported in 2 patients (6%). The most common AEs considered, at least possibly related to study drug were chills, reported in 4 patients (12%). Only 5 other AEs considered related to study treatment were reported in more than 1 patient: chest discomfort, flushing, nausea, pruritus and alanine aminotransferase (ALT) increased. Eleven patients experienced a total of 31 serious adverse events (SAEs). Two patients experienced SAEs considered at least possibly related to study drug consistent with infusion-related reactions at approximately month 6; both of these patients were antibody-positive at Month 3. General disorders and administration site conditions were reported in 6 patients (18%). One AE in this SOC (one incidence of chills) was considered severe. One patient withdrew from the study due to an SAE consistent with an infusion reaction. Another patient withdrew due to a diagnosis of lung cancer.
A Phase IV, multicenter, randomized study (CZ-011-01) was conducted to assess the safety and efficacy of Cerezyme infusions every four weeks (Q4) versus every two weeks (Q2), at the same cumulative dose, in the maintenance therapy of patients with Type 1 Gaucher Disease (n = 37 Q2; n = 65 Q4). Five (8.4%) patients from the Q4 and 1 (3.0%) patient from the Q2 groups withdrew from the study due to adverse events. All 5 of the Q4-treated patients withdrew due to symptoms consistent with Gaucher disease. These symptoms include splenomegaly, decreased hemoglobin, arthralgia, and bone pain. Treatment emergent AEs were reported in the Q4 (83.9%) and Q2 (63.6%) groups. The AEs (≥ 5% and occurring more often in Q4 group than in the Q2 group) are: back pain (16.1% vs. 0%), arthralgia (16.1% vs. 9.1%), fatigue (9.7% vs. 0%), headache (9.7% vs. 6.1%), decreased hemoglobin (8.1% vs. 0%), platelet count decreased (8.1% vs. 0%), bone pain (8.1% vs. 6.1%), pain in extremity (8.1% vs. 6.1%), sinusitis (8.1% vs. 6.1%), gastroenteritis viral (6.5% vs. 0%), influenza (6.5% vs. 0%) and, cough (6.5% vs. 3.0%). The AEs considered as related to study medication were approximately twice the rate in the Q4 group compared to the Q2 group (11.3% vs. 6.1%). They are fatigue, pain in extremity, infusion site erythema, infusion site pain, dizziness, tremor, hemoglobin decreased and splenomegaly. The most commonly reported infusion-related reactions include: pruritus, urticaria, muscle spasms, fatigue, infusion site erythema, and infusion site pain. There were 2 (3.2%) patients in the Q4 group, none in the Q2 group, who experienced infusion site erythema or infusion site pain. Two patients (3.2%) in the Q4 group reported hypersensitivity and multiple allergies. No immune system disorders were reported in Q2-treated patients.
Immunogenicity
As with all therapeutic proteins, there is a potential for immunogenicity (see 7 WARNINGS AND PRECAUTIONS, Immune). The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
A voluntary immunosurveillance program was initiated in 1991 to better determine the extent of antibody formation in patients receiving alglucerase, which was then extended to patients receiving imiglucerase treatment. The Sponsor offers this service to the Gaucher-treating physicians world-wide. As part of the immunosurveillance program, patients are monitored for the development of IgG antibodies to the enzyme using an ELISA test. The resultant absorbance values are compared to a cut-off established from a normal human serum distribution study. Confirmation by the radioimmunoprecipitation (RIP) test of the “above normal range” ELISA indicates that the patient developed antibodies to glucocerebrosidase.
During post-marketing safety surveillance of imiglucerase, the seroconversion rate in patients treated with imiglucerase only has remained at approximately 15%. This overall seroconversion rate is consistent with the rate of antibody formation in patients treated with imiglucerase only reported in the US Pivotal/Extended (3/15, 20%) and Israeli (1/10, 10%) Studies. Patients who develop IgG antibody largely do so within 6 months of treatment and rarely develop antibodies to imiglucerase after 12 months of therapy. Infusion-associated reactions have been reported in approximately half of patients with detectable IgG antibodies to imiglucerase. The most commonly reported symptoms, which are mostly mild to moderate in nature, include pruritus, rash, urticaria, headache, dyspnea and chills. Reactions in most cases are managed by a slower infusion rate and/or pretreatment with anti-pyretics or antihistamines. Patients with antibodies to imiglucerase have a higher risk of infusion-associated reactions; however, not all patients experiencing infusion-associated reactions have detectable IgG antibodies. It is suggested that patients be monitored periodically for IgG antibody formation.
9 DRUG INTERACTIONS
9.4 Drug-Drug Interactions
Interactions with other drugs have not been established.
9.5 Drug-Food Interactions
Interactions with food have not been established.
9.6 Drug-Herb Interactions
Interactions with herbal products have not been established.
9.7 Drug-Laboratory Test Interactions
Interactions with laboratory tests have not been established.
10 CLINICAL PHARMACOLOGY
10.1 Mechanism of Action
Imiglucerase is an analogue of ß-glucocerebrosidase produced by recombinant DNA technology. The lysosomal enzyme catalyses the hydrolysis of glucocerebroside to glucose and ceramide. Gaucher disease is an autosomal genetic disorder characterized by a deficiency of ß-glucocerebrosidase activity, resulting in accumulation of glucocerebroside in the lysosomes of tissue macrophages in the liver, spleen, bone marrow and occasionally in lung and kidney. Secondary hematologic sequelae include severe anemia and thrombocytopenia in addition to the characteristic progressive
hepatosplenomegaly, skeletal complications, including osteonecrosis and osteopenia with secondary pathological fractures.
10.2 Pharmacodynamics
Imiglucerase (recombinant macrophage targeted acid ß-glucosidase) replaces the deficient enzyme activity, hydrolysing glucosylceramide, thus correcting initial pathophysiology and preventing secondary pathology. In clinical trials, imiglucerase reduces spleen and liver size, improves thrombocytopenia and anemia, improves bone marrow burden, and reduces bone pain and bone crises. Patients have been shown to consistently respond to therapy regardless of the heterogeneity or severity of Gaucher disease. Pediatric patients generally respond to ERT more quickly than adults. The skeletal response in both pediatric and adult patients to ERT is generally slower than the hematologic and organ response. The initial primary uptake sites of imiglucerase are the spleen and liver.
In a Phase IV open-label study (RC96-1101) in patients with Type 1 Gaucher disease, 33 patients received 60 U/kg of imiglucerase every 2 weeks for the first 24 months. If therapeutic goals had been met, the patient could maintain the current imiglucerase dose or the dose could be reduced to 45 U/kg or 30 U/kg every 2 weeks. Reduction in bone pain was observed with imiglucerase treatment by Month 3. Among the 32 patients with follow-up data, 12 patients (38%) who had moderate, severe, or extreme pain at baseline, had dropped to 6 (19%) by Month 3. The number of patients with no pain had risen from 9 (28%) at baseline to 16 (52%), 65% and 60% on months 6, 21 and 48. While 13 patients were reported to have a history of bone crises and 5 patients reported at least one bone crisis within the 2 months prior to baseline, bone crises were reported in only 3 patients in the 48 months of the study.
10.3 Pharmacokinetics
Table 7: Summary of Pharmacokinetic Data
| Report # | Descrip-tion | Type of analysis | Cmax | AUC | t½ [min]1 | Vd [L/kg]1 | Cl [mL/(min.kg)]1 |
| RC92-0502 | Gaucher patients | Enzymatic activity* | Not evaluated | Not evaluated | 5.9 | 0.159 | 18.9 |
*p-nitrophenyl-ß-D-glucopyranoside (pNP-ß-D-glucopyranoside) as a substrate. An enzyme unit (U) is defined as the amount of enzyme that catalyses the hydrolysis of one micromole of the synthetic substrate p-nitrophenyl ß-D-glucopyranoside (pNP-Glc) per minute at 37 ºC.
1Mean values reported.
Absorption: Imiglucerase is administered IV. During one hour intravenous infusions of four doses (7.5, 15, 30, 60 U/Kg) of imiglucerase steady-state enzymatic activity was achieved by 30 minutes.
Distribution: The volume of distribution corrected for weight ranged from 0.09 to 0.15 L/Kg (0.12 ± 0.02 L/kg). These variables appear to be independent of dose or duration of infusion. Within the dose range of 7.5 to 60 U/kg, volume of distribution values appear to be independent of the infused dose.
Metabolism: Imiglucerase is not a substrate for drug metabolizing enzymes.
Elimination: Similar to other enzymes, imiglucerase is broken down by endogenous protease and peptidase. Following infusion, plasma enzymatic activity declined rapidly with a half-life ranging from 3.6 to 10.4 minutes. Plasma clearance ranged from 9.8 to 20.3 mL/min/Kg, (mean ± S.D, 14.5 ± 4.0 mL/min/Kg). Within the dose range of 7.5 to 60 U/kg, elimination half-life and plasma clearance appear to be independent of the infused dose.
11 STORAGE, STABILITY AND DISPOSAL
Lyophilized vial
Table 8: Storage for Lyophilized vial
| Cerezyme | Temperature | Recommended maximum storage time |
| lyophilized vial | 2-8 ºC | Do not use past expiry date on label |
| lyophilized vial | 23-27 ºC | do not exceed 48 hours |
Reconstituted Solutions
Stability of reconstituted and diluted solutions are noted below:
Table 9: Storage for Reconstituted Solutions
| Cerezyme Condition | Temperature | Recommended maximum storage time |
| Reconstituted vial (WFI) | 2-8 ºC | up to 12 hours |
| Reconstituted vial (WFI) | 28-32 ºC | up to 12 hours |
| Diluted with 0.9% NaCl | 2 – 8 ºC | up to 24 hours |
| Diluted with 0.9% NaCl | 20 – 25 ºC | up to 24 hours |
Note: Reconstituted vials of Cerezyme are single use only. Use the vials immediately upon reconstitution. Additionally, Cerezyme when diluted with saline, has been shown to be stable for up to 24 hours when stored at room temperature and at 2-8ºC.
PART II: SCIENTIFIC INFORMATION
13 PHARMACEUTICAL INFORMATION
Drug Substance:
Proper name: Imiglucerase
Chemical name: Recombinant human carbohydrate-modified ß-glucocerebrosidase
Molecular formula and molecular mass: C2532H3845N671O711S16 / Mr = 60,430 (as determined by Mass Spectroscopy)
Structural formula:
Provided below is the structural formula of glucocerebroside and the site of action of glucocerebrosidase (GCR).
+ O OH O HO HO OH CH OH 2 CH2 O HO HO OH CH OH 2 GCR 2H O N O OH HOCH2 N O OH
Physicochemical Properties:
Imiglucerase, an analogue of the human enzyme β-glucocerebrosidase, is a lysosomal glycoprotein enzyme which catalyses the hydrolysis of the glycolipid glucocerebroside to glucose and ceramide. Imiglucerase has oligosaccharide chains, which have been modified to terminate in mannose sugars. These mannose-terminated oligosaccharide chains of imiglucerase are specifically recognized by endocytic carbohydrate receptors on macrophages, the cells that accumulate lipid in Gaucher disease.
Product Characteristics:
Cerezyme (imiglucerase for injection) is a sterile, non-pyrogenic, white to off-white lyophilized powder. Imiglucerase is manufactured in Chinese Hamster Ovary (CHO) cells using a cell culture and expansion process, and purified using a series of chromatographic and membrane filtration. The imiglucerase Drug Substance is formulated with formulation buffer, processed through a nanofilter, and adjusted to achieve the final protein concentration. The Formulated Drug Substance is then pooled, sterile filtered, filled aseptically into glass vials, and lyophilized to produce the Drug Product. The lyophilized vials are then capped, labelled and packaged.
Viral Inactivation:
The viral safety of Cerezyme is confirmed by a combination of selection and qualification of vendors, raw material testing, cell bank characterization studies, validation of the viral removal and inactivation capacity of the purification process, and routine in-process testing.
14 CLINICAL TRIALS
14.1 Clinical Trials by Indication
Gaucher Disease
Table 10: Summary of patient demography for clinical trials in long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit non-neurological manifestations of the disease
| Study # | Trial design | Dosage, route of administration and duration | Study subjects (n=number) | Mean age (Range) | Gender |
RC91-0110 Pivotal Trial | Randomized, controlled, double blind, parallel | Cerezyme 60 U/kg or alglucerase injection 60 U/kg every 2 weeks, intravenous infusion, 6 months | Gaucher patients (n = 30) | 32.7 years (12 to 69 years) | 17 M / 13 F |
RC92-0501 Extension to Pivotal Trial (RC91-0110) | Randomized, controlled, double blind, parallel | Cerezyme 60 U/kg every 2 weeks, intravenous infusion, 26 to 29 months* | Gaucher patients (n = 30)** | 32.7 years (12 to 69 years) | 17 M / 13 F |
| RC92-0301 | Randomized, controlled, matched pair | Cerezyme 15 U/kg every 2 weeks or Cerezyme 2.5 U/kg 3 times a week, intravenous infusion, 1.5 to 2 years | Gaucher patients (n=10) | 32.2 years (18 to 46 years) | 2 M / 8 F |
| CZ-011-01 | Open-label, randomized | Cerezyme 40-120 U/kg in a 4-week period. Total 4-week dose in 2 infusions (1 infusion/2 weeks), Q2; or total 4-week dose in 1 infusion, Q4, intravenous infusion, 24 months | Gaucher patients (n=95)*** | 46.8 years (18 to 82 years) | 48 M / 47 F |
*Patients in extension study RC92-0501 initially received doses of Cerezyme at 60 U/kg which was reduced at the 9 month evaluation period. Doses were adjusted based upon achievement of specified hematological responses, but not skeletal responses.
**Twenty-nine patients completed treatment on Cerezyme.
*** One hundred two patients were randomized to treatment but 95 patients received one ore more doses of study treatment.
After the completion of the pivotal trial (RC91-0110), at 6 months, patients continued to be followed for an extended study period (RC92-0501) of 26 to 29 months. In addition, a separate dosing schedule comparison study (RC92-0301) was conducted. In the pivotal trial, some initial positive effects on bone were observed but according to protocol design, doses were reduced once hematologic improvements were achieved. Reports in the literature indicate that effects on bone may require longer treatment with higher doses. The tables below describe the results of these studies.
Table 71: Clinical Effects on Hematology and Organ Weights (% change compared to baseline):
| Report # | Parameter | Hemoglobin | Platelet | Liver | Spleen |
RC91-110 Pivotal Trial Cz arm N15 (6 months results change compared to baseline): | Mean | 20% | 33% |
|
|
| p value | p < 0.001 | p = 0.001 | p <0.001 | p <0.001 | |
| Response | ↑ ≥ 1.0 g/dL | ↑ ≥ 30% | ↓ ≥ 10% | ↓ ≥ 10% | |
| Response rate | 13/15 87% | 9/15 60% | 8/15 53% | 15/15 100% | |
RC92-0501 Extension (28 months results compared to baseline) | Mean | 28% | 80% |
|
|
| Response | ↑ ≥ 1.0 g/dL | ↑ ≥ 30% | ↓ ≥ 10% | ↓ ≥ 10% | |
| Response rate | 12/15 80% | 11/15 73% | 14/15 93% | 14/15 93% | |
RC92-0301 (2-year period) | Mean | 12.5% | 97% |
|
|
| Response | ↑ ≥ 1.0 g/dL | ↑ ≥ 30% | ↓ ≥ 10% | ↓ ≥ 10% | |
| Response rate | 7/10 70% | 5/10 50% | 7/10 70% | 9/10 90% |
Effects on Bone:
Long term changes in cortical bone thickness and radiographic assessment were evaluated in a group of 11 patients who participated in the Pivotal/Extended study. Cortical thickness was evaluated as the difference between the periosteal and endosteal diameters at the midshaft of the bone.
Table 82: Long term changes in cortical bone thickness and radiographic assessment
| Measurement | % improvement from baseline | N |
| Cortical thickness of the Humeri | 43% | 3 out of 7 evaluated |
| Cortical thickness of the Femora | 60% | 6 out of 10 evaluated |
| Radiographic Assessment | 63% | 7 out of 11 evaluated |
Effects on Clinical Stability for Varied Dosing Regimens:
The usual frequency of infusion is once every 2 weeks (see 4 DOSAGE AND ADMINISTRATION). Maintenance therapy every 4 weeks (Q4) at the same cumulative dose as the bi-weekly (Q2) dose has been studied in adult patients with stable residual Gaucher disease type 1. A total of 102 patients (37 Q2, 65 Q4) were randomized to treatment and 95 patients (33 Q2, 62 Q4) received one or more doses of study treatment. A total of 80 patients were included in the analysis at month 12 (27 Q2, 53 Q4) and a total of 83 patients were included in the analysis at month 24 (26 Q2, 57 Q4). The mean age at randomization in the Q2 group was 44.8 (19-82) and in the Q4 group was 47.8 (18-78).
Changes from baseline in hemoglobin, platelets, liver and spleen volumes, bone crises, and bone disease comprised a predefined composite endpoint; The primary efficacy endpoint was the proportion of patients with a clinical success (success rate). Patients were considered to be a clinical success if ALL of the following were met:
- The patient’s hemoglobin did not fall more than 1.25 g/dL for women or 1.5 g/dL for men below the patient’s baseline value.
- The patient’s platelet count did not fall more than 25% below the patient’s baseline value and did not fall below 80,000 mm3.
- The patient’s liver and spleen volumes were not greater than 20% above the patient’s baseline value.
- The patient had no new on-study finding or progression of bone disease, including no new incidence of pathologic fractures, medullary infarctions, lytic lesions or avascular necrosis.
- The patient had no bone crises during the study.
In the Q2 group, the mean infusion dose received by patients was 66.7 U/Kg/4wk (range 37-118) and the mean infusion duration was 182.3 minutes/4wk (range 119-316). In the Q4 group, the mean infusion dose received by patients was 69 U/Kg/4wk (range 29-120) and the mean infusion duration was 135.9 minutes/4wk (range 60-306). Fifty-three percent (n=33) of Q4-treated patients received the high dose Cerezyme (>60 U/kg Cerezyme every 4 weeks) compared with 36% (n=12) of Q2-treated patients.
Of ITT patients with a known clinical outcome, a total of 63% of Q4-treated patients met the criteria for clinical success at Month 24/discontinuation compared with 81% of Q2-treated patients. The success rates at Month 12 for Q4 was 60% and for Q2 was 96%. Two Q2 (6%) and 13 Q4 patients (21%) withdrew due to clinical failure.
Of ITT patients, 0 of the Q2 treated patients had a liver size increase from baseline ≥20% at 12 months of treatment and 1 (3%) had an increase from baseline ≥20% at 24 months of treatment. Five (8%) of the Q4 treated patients had liver size increases from baseline ≥20% at 12 months of treatment and 2 (3%) had increases from baseline ≥20% at 24 months of treatment. Of ITT patients, 0 of the Q2 treated patients had a spleen size increase from baseline ≥20% at 12 months of treatment and 2 (6%) had an increase from baseline ≥20% at 24 months of treatment. Seven (11%) of the Q4 treated patients had spleen size increases from baseline ≥20% at 12 months of treatment and 4 (6%) had increases from baseline ≥20% at 24 months of treatment.
Effects on Neurological Manifestations:
No controlled clinical studies have been conducted on the efficacy of Cerezyme on neurological manifestations of the disease. Therefore no conclusions on the effect of enzyme replacement therapy on the neurological manifestations of the disease can be drawn.
Effects on Gaucher Patients (Type 3):
Evaluation of treatment efficacy data captured from the International Collaborative Gaucher Group Registry (ICGG/Gaucher Registry) and from a Japanese post-marketing study show evidence of improvement in non-neurological manifestations (anemia, thrombocytopenia, bone disease, hepatomegaly, and splenomegaly) for Type 3 patients, similar to that observed in Type 1 patients.
The post-marketing clinical study performed in Japan was designed as an open study for patients with Type 2 and Type 3 Gaucher disease. It was designed to address conditions for approval of Cerezyme in Japan. The aim of the study was to assess the efficacy and safety of the drug in the commercial setting over 3 years.
Separate analyses of the safety and efficacy for the Type 3 patients in the Japanese study were performed. Results showed that laboratory parameters such as Hemoglobin, Platelet count, ACE activity and ACP activity were dramatically improved within 24-48 weeks and maintained until the end of the study (144 weeks). Size and volume of liver or spleen were decreased within 24 weeks and maintained until the end of the study (144 weeks). General symptoms could have improved in some patients, but efficacy for bone or neurological symptoms were very limited. However, physicians judged overall improvement was found at rate of 50% and clinical efficacy of ERT was confirmed to all of Type 3 patient. Safety profile was acceptable. Only one patient experienced an adverse event of nail disorder which was considered potentially related to Cerezyme therapy. Unrelated but serious adverse events reported included: pneumonia, complications of bone marrow transplant, acute cholecystitis, cholelithiasis, convulsions, aspiration pneumonia, bronchitis, intestinal obstruction, inguinal hernia, pyrexia, urticaria, increased bronchial secretions, respiratory failure, femur fracture and tonsillar hypertrophy. The majority of unrelated, serious events recorded in the patients with Type 3 disease are related to the nature of the severe underlying Gaucher disease.
In addition to the Japanese data, multiple analyses comparing the hematological (hemoglobin, platelets) and visceral (liver, spleen) responses to ERT in chronic neuronopathic (Type 3) versus non-neuronopathic (Type 1) Gaucher patients were performed using data from the Gaucher Registry from a total of 2637 patients. This data set consisted of 130 neuronopathic Gaucher patients, of whom 117 have received ERT. In respect to platelet responses, the presented data suggest that the responses to ERT are at least similar in both patient populations.
In regards to platelet count, the responses to therapy from patients in the Registry seem to be most prominent in the first 2 years of treatment and the patients’ ability to have an increase of platelet counts in response to ERT does not seem to be influenced by the presence or absence of the spleen.
In the first 6 months of treatment, the majority (83%) of neuronopathic patients showed amelioration of thrombocytopenia resulting in reclassification of thrombocytopenia severity from “severe” to “moderate” / ”normal”, compared to one third (35%) of the “severe” non-neuronopathic population.
For hemoglobin, the majority of patients in both patient populations start treatment with moderate to severe anemia, and reach normal or near normal hemoglobin values within the first 12 or 18 months of treatment.
In the first 6 months of treatment, 64% of neuronopathic patients showed improvement of their anemia resulting in reclassification of anemia severity from “severe” to “moderate” / ”normal”, compared to 69% of the severely anemic non-neuronopathic population.
In both populations, the liver volumes decrease, as indicated by the mean and median reduction in liver volume MN at 12 and 24 months and a reduction in severity of hepatomegaly category distribution during the first 6 months of treatment.
Both patient groups had moderate to severe splenomegaly at baseline, and demonstrated improvement over time. Despite the substantial reduction in spleen size, the majority of neuronopathic patients still fall within the severe splenomegaly category (> 15 x MN) after 6 months of enzyme replacement therapy, indicating relatively severe underlying disease.
In the short term (6 month) analyses of change from baseline for all the parameters tested, the experience of neuronopathic patients is always numerically superior to that of non-neuronopathic patients. The 12 to 24 month analyses tend to confirm the initial response results. Virtually all measurements of change from baseline are larger among neuronopathic patients than among non-neuronopathic patients. The more severe systemic manifestations at baseline in the neuronopathic population and the higher ERT doses used in neuronopathic Gaucher disease may have influenced these observations.
In conclusion, the analyses of the Registry data show a comparable response to ERT between non-neuronopathic and neuronopathic Gaucher patients with regard to the systemic manifestations of Gaucher disease, as measured by the parameters analysed.
15 MICROBIOLOGY
No microbiological information is required for this drug product.
16 NON-CLINICAL TOXICOLOGY
General Toxicology:
Table 93: Overview of toxicology studies
| Report # | Study Characteristics | Parameters Evaluated | Results |
| HWI 6354-102 | Rat Single dose 0, 60, 300, 600 U/kg IV 5M, 5F per group | clinical, food consumption, body weight, hematology, clinical chemistry, organ weight, necropsy, histology | Statistically significant increased platelet and hemoglobin. Increased neutrophil count in 600 u/kg males. |
| BDL 12807 | Rat 13 weeks 0, 3, 30, 300 U/kg IV 5M, 5F per group | clinical, food consumption, body weight, hematology, clinical chemistry, urinalysis, organ weight, necropsy, histology | Dose-dependant antibody response in >50% of animals. |
| CHV 6354-109 | Monkey 13 weeks 0, 30, 100, 300 U/kg IV 3M, 3F per group | clinical, body weight, hematology, clinical chemistry, urinalysis, organ weight, necropsy, histology | Statistically significant increase in mean spleen weight, spleen-to-body weight ratio, spleen-to-brain ratio in 300 u/kg females. Dose-dependant antibody response in >50% of animals. |
Carcinogenicity: No long-term animal studies have been performed to evaluate the carcinogenic potential of imiglucerase.
Genotoxicity: Imiglucerase was tested using the Ames mutagenicity test and all concentrations, both with and without activation, were negative.
Reproductive and Developmental Toxicology: No animal studies have been performed to evaluate the effects of imiglucerase on fertility/reproduction, embryo-fetal development, or post-natal development.
Juvenile Toxicity: No animal studies have been performed to evaluate the potential toxicity of imiglucerase in juvenile animals.
